Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aprepitant for prevention of chemotherapy-induced nausea and vomiting in germ cell tumour patients receiving cisplatin
ACTRN12608000254392Phase 2Completed
- Sponsor
- The University of Sydney
- Start
- Apr 2009
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of aprepitant in chemotherapy-induced nausea and vomiting (CINV) (2 arms), sponsored by The University of Sydney. Primary endpoint: No emesis during day 1 and days 1 to 8 of cycle 1. Started Apr 2009; status: completed.
02
Drugs
aprepitant
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on ACTRN12608000254392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12608000254392.